From Bench to Bedside: A Comprehensive Study on Pardaxin Peptide's Antimicrobial Effect on Escherichia coli, Including Clinical Isolates

Document Type : Original Articles

Authors

Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.22092/ari.2024.364221.2950

Abstract

Escherichia coli is a common cause of urinary tract infections and it has shown increasing resistance to available antimicrobial agents. Antimicrobial peptides, such as Pardaxin, offer a potential alternative to antibiotics due to their ability to disrupt the cell membrane of bacteria through their interaction with the lipid bilayer. This mode of action provides an advantage by reducing the likelihood of resistance development compared to traditional antibiotics that target specific cellular processes. The objective of this study was to assess the antimicrobial efficacy of the Pardaxin peptide against both standard and clinical strains of E. coli. E. coli ATCC 25922 was used as the standard strain, and 20 samples of E. coli derived from patients were included in the study. Isolation and identification of E. coli were done by using enrichment media, selective media, and biochemical tests. Bacterial culture was conducted on Mueller-Hinton agar, and the antimicrobial effect of the Pardaxin peptide was assessed using classic disk diffusion tests. During the disk diffusion test, we observed a distinct area of no growth surrounding the Pardaxin material for both the standard and clinical strains. In the microdilution test, the minimum inhibitory concentration of Pardaxin was 390 µg/ml for the clinical strain and 450 µg/ml for the standard strain, which is an acceptable concentration compared to the concentration of 500 µg/ml erythromycin and indicates the antibacterial properties of Pardaxin on E. coli. The results of this study provide evidence for the antimicrobial properties of the Pardaxin peptide against both standard and clinical strains of E. coli.

Keywords

Main Subjects